Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Cadherin

Cadherins are a class of calcium-dependent cell adhesion proteins that mediate intercellular adhesion and signal transduction through homodimerisation, playing a pivotal role in embryonic development, tissue differentiation, and the maintenance of intercellular junctions. The cadherin family comprises numerous members, including E-cadherin (epithelial cell adhesion molecule) and N-cadherin (neuronal cell adhesion molecule). E-cadherin is primarily expressed in epithelial cells, where it is essential for maintaining epithelial polarity and tissue integrity. N-cadherin, conversely, plays a vital role in neural tissues, participating in neuronal migration and synapse formation. Dysfunction of cadherins is implicated in various diseases, including tumour invasion and metastasis, as well as neurodegenerative disorders

MC-1-F2
T696592376894-10-7In house
MC-1-F2 is a direct FOXC2 inhibitor with anticancer activity, inhibits cancer stem cell (CSC) characteristics, and reduces the invasive ability of castration-resistant prostate cancer (CRPC) cell lines. MC-1-F2 can be used to study prostate cancer.
  • $256
In Stock
Size
QTY
Tralokinumab
LP 0162, CAT-354
T767041044515-88-9
Tralokinumab is a fully human IgG4 monoclonal antibody with a high affinity for IL-13 alone. Tralokinumab's potential anti-inflammatory activity prevents IL-13 receptor interaction and subsequent downstream signaling and can be used to study atopic dermatitis (AD).
  • $289
In Stock
Size
QTY
N-​Feruloyloctopamine
N-Feruloyloctopamine
TN196866648-44-0
N-Feruloyloctopamine is a natural product.
  • $77
In Stock
Size
QTY
ADH-1
Exherin
T2637229971-81-7
ADH-1 (Exherin) is an N-cadherin antagonist, inhibits N-cadherin mediated cell adhesion with potential antineoplastic and antiangiogenic activities.
  • $52
In Stock
Size
QTY
TargetMol | Citations Cited
INS018 055
TNIK&MAP4K4-IN-2, INS018055
T875452828567-39-9
INS018 055 (TNIK&MAP4K4-IN-2) is a highly efficient TNIK and MAP4K4 inhibitor with antifibrotic activity. It can be used in research on idiopathic pulmonary fibrosis.
  • $68
In Stock
Size
QTY
Aristolactam I
Aristololactum, Aristololactam I, Aristolactam
T3S122713395-02-3
1.Aristolactam I (Aristololactum) has cytotoxic potency, mediated through the induction of apoptosis in a caspase 3-dependent pathway. 2. The effects of Aristololactam I may be mediated by different mechanisms except TGF-beta1 pathway. 3. Aristololactam I may be one of toxic metabolites in Chinese herbs containing AA which participate in renal damage and fibrosis.
  • $55
In Stock
Size
QTY
Lycorine hydrochloride
Narcissine hydrochloride, Lycorine chloride, Licorine hydrochloride, Galanthidine hydrochloride, Amarylline hydrochloride
T27742188-68-3
Lycorine hydrochloride (Narcissine hydrochloride) is VE-cadherin inhibitor,and has IC50 of 1.2μM in Hey1B cell.It is an HCV inhibitor with strong activity.
  • $39
In Stock
Size
QTY
TargetMol | Citations Cited
ML327
T42521883510-31-3
ML327 is a MYC blocker. ML327 can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).
  • $42
In Stock
Size
QTY
ADH-1 trifluoroacetate
Exherin trifluoroacetate
T16081135237-88-5
ADH-1 trifluoroacetate (Exherin trifluoroacetate) is a cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities. ADH-1 selectively and competitively binds to and blocks N-cadherin, which may result in disruption of tumor vasculature, inhibition of tumor cell growth, and the induction of tumor cell and endothelial cell apoptosis.
  • $37
In Stock
Size
QTY
Cadherin Peptide, avian Acetate
Cadherin Peptide, avian Acetate (127650-08-2 Free base)
T21662L
Cadherin Peptide, avian Acetate is a peptide with the sequence Leu-Arg-Ala-His-Ala-Val-Asp-Val-Asn-Gly-NH2. Cadherins are a class of type-1 transmembrane proteins.
  • $57
In Stock
Size
QTY
TargetMol | Inhibitor Sale
PF-03732010
PF03732010
T77475
PF-03732010 is a CHO-expressed humanized antibody targeting P-calmodulin with anti-tumor and anti-metastatic activity, inhibiting primary tumor growth and metastatic progression.
  • $197
In Stock
Size
QTY
Raludotatug
T813132610074-56-9
Raludotatug is a humanized immunoglobulin G1-kappa (IgG1κ) monoclonal antibody that exhibits antineoplastic properties through its specific targeting of cadherin-6 (CDH6), and when conjugated to a cytotoxic payload to form the antibody-drug conjugate Raludotatug deruxtecan.Raludotatug has demonstrated promising research potential in heavily pretreated, platinum-sensitive ovarian cancer.
  • $247
In Stock
Size
QTY
PTA001_A4
Anti-CDH17/Cadherin-17 Antibody
T9901A-081
PTA001_A4 (Anti-CDH17/Cadherin-17 Antibody) is a humanized antibody targeting CDH17/Cadherin-17 with potential anti-tumor activity, inhibits the growth of tumor cells, and can be used for cancer research.
  • $195
In Stock
Size
QTY
Zarutatug
T9901A-18313038456-02-6
Zarutatug is a humanized IgG1κ antibody with antitumor activity targeting CDH17 (cadherin 17). The recommended isotype control for this antibody is Human IgG1kappa, Isotype Control.
  • Inquiry Price
Inquiry
Size
QTY
AL-GDa62
T61815
AL-GDa62, a potential synthetic lethal agent for gastric cancer treatment, demonstrates efficacy with EC50 values of 3.2 μM in MCF10A-WT (wild-type) isogenic mammary epithelial cells and 2 μM in MCF10A-CDH1 -/- cells [1].
  • $1,520
10-14 weeks
Size
QTY
HDAC-IN-55
T785321268674-16-3
HDAC-IN-55(8j) is a small-molecule inhibitor that enhances E-cadherin expression and suppresses cancer cell proliferation [1].
  • Inquiry Price
8-10 weeks
Size
QTY
Anti-CDH17/Cadherin-17 Antibody (10C12)
T9901A-821
Anti-CDH17/Cadherin-17 Antibody (10C12) is a human-derived antibody produced in CHO cells, targeting CDH17. For isotype control, refer to HumanIgG1kappa, Isotype Control.
  • Inquiry Price
Inquiry
Size
QTY
CQY684
PCA062 antibody
T9901A-1609
CQY684 (PCA062 antibody) is a human monoclonal antibody (mAb) that targets CDH3/P-cadherin. It stabilizes the X-dimer of P-cadherin, facilitating its endocytosis and directing it towards lysosomal degradation. CQY684 is applicable in studies of breast cancer, esophageal cancer, and head and neck cancers.
  • Inquiry Price
Inquiry
Size
QTY
CPS-021
T211043
CPS-021 is a selective PAK4PROTAC degrader with a DC50 of 50 nM. It demonstrates potent anti-migration and anti-invasion properties, significantly inhibiting the invasion and metastasis of tumor cells in an A549-luc lung metastasis mouse model.
  • Inquiry Price
Inquiry
Size
QTY
anti-TNBC agent-9
T206779
Anti-TNBC agent-9 (Compound 3as) is an anticancer agent used for treating triple-negative breast cancer (TNBC). It exhibits significant inhibitory activity against MDA-MB-453 cells, with an IC50 value of 8.5 μM. Anti-TNBC agent-9 impedes tumor cell migration by upregulating E-cadherin and downregulating N-cadherin, matrix metalloproteinase 2 (MMP2), and MMP9. Additionally, it inhibits tumor cell proliferation by inducing apoptosis, achieved through the increased expression of pro-apoptotic protein BAX and decreased expression of anti-apoptotic protein BCL-2.
  • Inquiry Price
Inquiry
Size
QTY
SLEC-11
T60639863761-17-5
SLEC-11 emerged as a synthetic lethal(SL) lead in E-cadherin-deficient cells which has potential for the treatment of gastric cancer.
  • $1,520
6-8 weeks
Size
QTY
Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1)
DECMA-1
T9901A-1172
Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) is an IgG1, κ inhibitor antibody derived from rats, targeting mouse E-Cadherin/CD324.
    Inquiry
    Cystatin B agonist 1
    T212012
    Cystatin Bagonist 1 is an orally active inhibitor of MMP-2/9. It suppresses U87 and T98G cells with IC50 values of 3.95 μM and 3.43 μM, respectively. Cystatin Bagonist 1 induces S-phase cell cycle arrest in MG cells and inhibits their angiogenesis, migration, and invasion. Additionally, it hinders tumor growth in U87 MG xenograft models. This compound is applicable for research in malignant glioma (MG).
    • Inquiry Price
    Inquiry
    Size
    QTY
    SF-9-2
    T2119603053768-78-5
    SF-9-2 is a PD-L1/PD-1 binding inhibitor with an IC50 of 24.9 nM. It suppresses epithelial-mesenchymal transition, migration, invasion, and proliferation of SK-N-SH cells, while also inducing apoptosis and causing cell cycle arrest. SF-9-2 blocks PD-L1-induced growth of SK-N-SH cells via the MAPK signaling pathway. It restores GSK-3β activity and enhances PD-L1 degradation through the ubiquitin-proteasome pathway. In the SK-N-SH NOG mouse model, SF-9-2 inhibits tumor growth without notable toxicity. Additionally, SF-9-2 acts as an immune checkpoint inhibitor, blocking PD-L1 to restore T cell function and is applicable to neuroblastoma research.
    • Inquiry Price
    10-14 weeks
    Size
    QTY